The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Open accessAbstract
Natural killer (NK) cells are essential components of the innate immune system and play a critical role in host immunity against cancer. Recent progress in our understanding of NK cell immunobiology has paved the way for novel NK cell-based therapeutic strategies for the treatment of cancer. In this review, we will focus on recent advances in the field of NK cell immunotherapy, including augmentation of antibody-dependent cellular cytotoxicity, manipulation of receptor-mediated activation, and adoptive immunotherapy with ex vivo-expanded, chimeric antigen receptor (CAR)-engineered, or engager-modified NK cells. In contrast to T lymphocytes, donor NK cells do not attack non-hematopoietic tissues, suggesting that an NK-mediated antitumor effect can be achieved in the absence of graft-vs.-host disease. Despite reports of clinical efficacy, a number of factors limit the application of NK cell immunotherapy for the treatment of cancer, such as the failure of infused NK cells to expand and persist in vivo. Therefore, efforts to enhance the therapeutic benefit of NK cell-based immunotherapy by developing strategies to manipulate the NK cell product, host factors, and tumor targets are the subject of intense research. In the preclinical setting, genetic engineering of NK cells to express CARs to redirect their antitumor specificity has shown significant promise. Given the short lifespan and potent cytolytic function of mature NK cells, they are attractive candidate effector cells to express CARs for adoptive immunotherapies. Another innovative approach to redirect NK cytotoxicity towards tumor cells is to create either bispecific or trispecific antibodies, thus augmenting cytotoxicity against tumor-associated antigens. These are exciting times for the study of NK cells; with recent advances in the field of NK cell biology and translational research, it is likely that NK cell immunotherapy will move to the forefront of cancer immunotherapy over the next few years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedCalamita, E., Schmid, M., Kunz, M., Ndebele-Murisa, M. R., Magadza, C. H. D., Nyambe, I., & Wehrli, B. (2019) · Figshare · doi:10.26181/6153922fe919c · Cited by 4,222
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“The CD56dim subset of NK cells expresses the Fcγ receptor CD16, through which NK cells mount ADCC, providing opportunities for its modulation to augment NK effector function (27, 28).”
BackgroundRosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Ferrara, J. L., Levine, J. E., Reddy, P., & Holler, E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60237-3 · Cited by 2,464
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., Carson, W. E., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.10.3146 · Cited by 1,449
Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming
Martín-Fontecha, A., Thomsen, L. L., Brett, S., Gerard, C., Lipp, M., Lanzavecchia, A., & Sallusto, F. (2004) · Nature Immunology · doi:10.1038/ni1138 · Cited by 1,353
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Lanier, L. L., Le, A. M., Civin, C. I., Loken, M. R., & Phillips, J. H. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.12.4480 · Cited by 1,129
Ferlazzo, G., Tsang, M. L., Moretta, L., Melioli, G., Steinman, R. M., & Münz, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011149 · Cited by 994
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Fauriat, C., Long, E. O., Ljunggren, H.-G., & Bryceson, Y. T. (2010) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 891
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Mamessier, E., Sylvain, A., Thibult, M.-L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Gonçalves, A., André, P., Romagné, F., Thibault, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45816 · Cited by 681
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
Romee, R., Foley, B., Lenvik, T., Wang, Y., Zhang, B., Ankarlo, D., Luo, X., Cooley, S., Verneris, M., Walcheck, B., et al. (2013) · Blood · doi:10.1182/blood-2012-04-425397 · Cited by 552
Campbell, J. J., Qin, S., Unutmaz, D., Soler, D., Murphy, K. E., Hodge, M. R., Wu, L., & Butcher, E. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6477 · Cited by 517
Human natural killer cell development and biology
Farag, S. S., & Caligiuri, M. A. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.10.001 · Cited by 506
Parkhurst, M. R., Riley, J. P., Dudley, M. E., & Rosenberg, S. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1347 · Cited by 475
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Chu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R., Carson, L. F., Argenta, P. A., Jonson, A. L., Panoskaltsis-Mortari, A., Curtsinger, J., McKenna, D., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2010.515582 · Cited by 436
Bachanova, V., Cooley, S., Defor, T. E., Verneris, M. R., Zhang, B., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lewis, D., Hippen, K., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532531 · Cited by 435
Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419
Natural killer cell biology: An update and future directions
Campbell, K. S., & Hasegawa, J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.006 · Cited by 416
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M. R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329508 · Cited by 406
De Maria, A., Bozzano, F., Cantoni, C., & Moretta, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012356108 · Cited by 344
Expression and Function of TNF-Related Apoptosis-Inducing Ligand on Murine Activated NK Cells
Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H., Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., & Yagita, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1906 · Cited by 340
Chang, Y.-H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3558 · Cited by 329
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, A., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 305
Berg, M., Lundqvist, A., McCoy, P., Samsel, L., Fan, Y., Tawab, A., & Childs, R. (2009) · Cytotherapy · doi:10.1080/14653240902807034 · Cited by 304
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis
Battula, V. L., Shi, Y., Evans, K. W., Wang, R.-Y., Spaeth, E. L., Jacamo, R. O., Guerra, R., Sahin, A. A., Marini, F. C., Hortobagyi, G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59735 · Cited by 302
Leong, J. W., Chase, J. M., Romee, R., Schneider, S. E., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.01.006 · Cited by 285
Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., et al. (2014) · Blood · doi:10.1182/blood-2013-08-519199 · Cited by 283
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Vey, N., Bourhis, J.-H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437558 · Cited by 278
Woll, P. S., Grzywacz, B., Tian, X., Marcus, R. K., Knorr, D. A., Verneris, M. R., & Kaufman, D. S. (2009) · Blood · doi:10.1182/blood-2008-06-165225 · Cited by 268
Jiang, H., Zhang, W., Shang, P., Zhang, H., Fu, W., Ye, F., Zeng, T., Huang, H., Zhang, X., Sun, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.001 · Cited by 267
Gleason, M. K., Ross, J. A., Warlick, E. D., Lund, T. C., Verneris, M. R., Wiernik, A., Spellman, S., Haagenson, M. D., Lenvik, A. J., Litzow, M. R., et al. (2014) · Blood · doi:10.1182/blood-2013-10-533398 · Cited by 266
Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment
Joncker, N. T., Shifrin, N., Delebecque, F., & Raulet, D. H. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100570 · Cited by 259
Della Chiesa, M., Falco, M., Podestà, M., Locatelli, F., Moretta, L., Frassoni, F., & Moretta, A. (2012) · Blood · doi:10.1182/blood-2011-08-372003 · Cited by 254
Burns, L. J., Weisdorf, D. J., DeFor, T. E., Vesole, D. H., Repka, T. L., Blazar, B. R., Burger, S. R., Panoskaltsis-Mortari, A., Keever-Taylor, C. A., Zhang, M.-J., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704086 · Cited by 252
Bellora, F., Castriconi, R., Dondero, A., Reggiardo, G., Moretta, L., Mantovani, A., Moretta, A., & Bottino, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007654108 · Cited by 246
Advantages and applications of CAR-expressing natural killer cells
Glienke, W., Esser, R., Priesner, C., Suerth, J. D., Schambach, A., Wels, W. S., Grez, M., Kloess, S., Arseniev, L., & Koehl, U. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00021 · Cited by 243
Spanholtz, J., Preijers, F., Tordoir, M., Trilsbeek, C., Paardekooper, J., de Witte, T., Schaap, N., & Dolstra, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020740 · Cited by 238
Shah, N. N., Baird, K., Delbrook, C. P., Fleisher, T. A., Kohler, M. E., Rampertaap, S., Lemberg, K., Hurley, C. K., Kleiner, D. E., Merchant, M. S., et al. (2015) · Blood · doi:10.1182/blood-2014-07-592881 · Cited by 238
Seidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 236
Stringaris, K., Sekine, T., Khoder, A., Alsuliman, A., Razzaghi, B., Sargeant, R., Pavlu, J., Brisley, G., de Lavallade, H., Sarvaria, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.087536 · Cited by 231
Self-citationWiernik, A., Foley, B., Zhang, B., Verneris, M. R., Warlick, E., Gleason, M. K., Ross, J. A., Luo, X., Weisdorf, D. J., Walcheck, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0505 · Cited by 226
Zhou, X., Dotti, G., Krance, R. A., Martinez, C. A., Naik, S., Kamble, R. T., Durett, A. G., Dakhova, O., Savoldo, B., Di Stasi, A., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628354 · Cited by 216
Tettamanti, S., Marin, V., Pizzitola, I., Magnani, C. F., Giordano Attianese, G. M. P., Cribioli, E., Maltese, F., Galimberti, S., Lopez, A. F., Biondi, A., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12282 · Cited by 211
Benson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., et al. (2011) · Blood · doi:10.1182/blood-2011-06-360255 · Cited by 208
Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pule, M., & Rossig, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2810 · Cited by 206
Improving the safety of cell therapy products by suicide gene transfer
Jones, B. S., Lamb, L. S., Goldman, F., & Di Stasi, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00254 · Cited by 201
A Central Role for Death Receptor-Mediated Apoptosis in the Rejection of Tumors by NK Cells
Screpanti, V., Wallin, R. P. A., Ljunggren, H.-G., & Grandien, A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.4.2068 · Cited by 201
Shah, N., Martin-Antonio, B., Yang, H., Ku, S., Lee, D. A., Cooper, L. J. N., Decker, W. K., Li, S., Robinson, S. N., Sekine, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076781 · Cited by 199
Self-citationBoissel, L., Betancur, M., Lu, W., Krause, D., Van Etten, R., Wels, W., & Klingemann, H. (2013) · OncoImmunology · doi:10.4161/onci.26527 · Cited by 194
Esser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D., Aperlo‐Iffland, C., Huston, J. S., Uherek, C., Schönfeld, K., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01343.x · Cited by 188
Yagita, M., Huang, C., Umehara, H., Matsuo, Y., Tabata, R., Miyake, M., Konaka, Y., & Takatsuki, K. (2000) · Leukemia · doi:10.1038/sj.leu.2401769 · Cited by 186
Wilcox, R. A., Tamada, K., Strome, S. E., & Chen, L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4230 · Cited by 181
Dalle, J.-H., Menezes, J., Wagner, É., Blagdon, M., Champagne, J., Champagne, M. A., & Duval, M. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000156501.55431.20 · Cited by 180
Shimasaki, N., Fujisaki, H., Cho, D., Masselli, M., Lockey, T., Eldridge, P., Leung, W., & Campana, D. (2012) · Cytotherapy · doi:10.3109/14653249.2012.671519 · Cited by 177
Stern, M., Passweg, J. R., Meyer-Monard, S., Esser, R., Tonn, T., Soerensen, J., Paulussen, M., Gratwohl, A., Klingebiel, T., Bader, P., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.162 · Cited by 176
Binyamin, L., Alpaugh, R. K., Hughes, T. L., Lutz, C. T., Campbell, K. S., & Weiner, L. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6392 · Cited by 176
Mononuclear myeloid-derived “suppressor” cells express RAE-1 and activate natural killer cells
Nausch, N., Galani, I. E., Schlecker, E., & Cerwenka, A. (2008) · Blood · doi:10.1182/blood-2008-03-143776 · Cited by 174
Antileukemia activity of a natural killer cell line against human leukemias.
Yan, Y., Steinherz, P. G., Klingemann, H., Dennig, D., Childs, B. H., McGuirk, J. P., & O’Reilly, R. J. (1998) · PubMed · Cited by 167
Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
Gras Navarro, A., Björklund, A. T., & Chekenya, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00202 · Cited by 167
Agaugué, S., Marcenaro, E., Ferranti, B., Moretta, L., & Moretta, A. (2008) · Blood · doi:10.1182/blood-2008-02-135871 · Cited by 165
Rouce, R. H., Shaim, H., Sekine, T., Weber, G., Ballard, B., Ku, S., Barese, C., Murali, V, Wu, M.-F., Liu, H., et al. (2016) · Leukemia · doi:10.1038/leu.2015.327 · Cited by 161
Self-citationNeuroblastoma-Derived TGF-β1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells
Castriconi, R., Dondero, A., Bellora, F., Moretta, L., Castellano, A., Locatelli, F., Corrias, M. V., Moretta, A., & Bottino, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202693 · Cited by 159
Choi, I., Yoon, S. R., Park, S.-Y., Kim, H., Jung, S.-J., Jang, Y. J., Kang, M., Yeom, Y. I., Lee, J., Kim, D., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.01.031 · Cited by 136
Tam, Y. K., Miyagawa, B., HO, V. C., & Klingemann, H.-G. (1999) · Journal of Hematotherapy · doi:10.1089/106161299320316 · Cited by 133
Lowdell, M. W., Craston, R., Samuel, D., Wood, M. E., O'Neill, E., Saha, V., & Prentice, H. G. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03495.x · Cited by 133
In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
de Haij, S., Jansen, J. H. M., Boross, P., Beurskens, F. J. M., Bakema, J. E., Bos, D. L., Martens, A. C., Verbeek, J. S., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4109 · Cited by 130
Yoon, S. R., Lee, Y. S., Yang, S., Ahn, K. H., Lee, J.-H., Lee, J.-H., Kim, D. Y., Kang, Y., Jeon, M., Seol, M., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.304 · Cited by 129
Lin, W., Voskens, C., Zhang, X., Schindler, D. G., Wood, A., Burch, E. E., Wei, Y., Chen, L., Tian, G., Tamada, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122465 · Cited by 124
Bradley, M., Zeytun, A., Rafi-Janajreh, A. Q., Nagarkatti, P. S., & Nagarkatti, M. (1998) · Blood · doi:10.1182/blood.v92.11.4248 · Cited by 119
Romain, G., Senyukov, V., Rey-Villamizar, N., Merouane, A., Kelton, W., Liadi, I., Mahendra, A., Charab, W., Georgiou, G., Roysam, B., et al. (2014) · Blood · doi:10.1182/blood-2014-04-569061 · Cited by 111
Kärre, K. (2002) · Science · doi:10.1126/science.1070538 · Cited by 109
Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors
Moretta, L., Pietra, G., Montaldo, E., Vacca, P., Pende, D., Falco, M., Zotto, G. D., Locatelli, F., Moretta, A., & Mingari, M. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00087 · Cited by 99
Natural killer cells in the treatment of high-risk acute leukaemia
Locatelli, F., Moretta, F., Brescia, L. P., & Merli, P. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.004 · Cited by 99
Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11
Liu, J., Xiao, Z., Ko, H. L., Shen, M., & Ren, E. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322052111 · Cited by 98
Lundqvist, A., Yokoyama, H., Smith, A. L., Berg, M., & Childs, R. W. (2009) · Blood · doi:10.1182/blood-2008-11-190421 · Cited by 91
Miller, J. S., Rooney, C. M., Curtsinger, J., McElmurry, R. T., McCullar, V., Verneris, M. R., Lapteva, N., McKenna, D. H., Wagner, J. E., Blazar, B. R., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.05.004 · Cited by 88
Natural killer cells: a review of manufacturing and clinical utility
Koepsell, S. A., Miller, J. S., & McKenna, D. H. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03724.x · Cited by 88
Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies
Pittari, G., Filippini, P., Gentilcore, G., Grivel, J., & Rutella, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00230 · Cited by 81
Swift, B. E., Williams, B. A., Kosaka, Y., Wang, X.-H., Medin, J. A., Viswanathan, S., Martínez‐López, J., & Keating, A. (2012) · Haematologica · doi:10.3324/haematol.2011.054254 · Cited by 74
Terszowski, G., Klein, C., & Stern, M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400288 · Cited by 73
Xing, D., Ramsay, A. G., Gribben, J. G., Decker, W. K., Burks, J. K., Munsell, M., Li, S., Robinson, S. N., Yang, H. Y., Steiner, D., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181e475e9 · Cited by 69
Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
Davies, J. O. J., Stringaris, K., Barrett, A. J., & Rezvani, K. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.03.009 · Cited by 65
Self-citationMurphy, W. J., Parham, P., & Miller, J. S. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.033 · Cited by 57
Differential activation of cord blood and peripheral blood natural killer cells by cytokines
Alnabhan, R., Madrigal, J. A., & Saudemont, A. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.08.003 · Cited by 56
Immunotherapy with gene-modified T cells: limiting side effects provides new challenges
Stauss, H. J., & Morris, E. C. (2013) · Gene Therapy · doi:10.1038/gt.2013.34 · Cited by 54
Murray, S. M., & Lundqvist, A. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1096458 · Cited by 51
Klingemann, H., Grodman, C., Cutler, E., Duque, M., Kadidlo, D. M., Klein, A., Sprague, K. A., Miller, K. B., Comenzo, R., Kewalramani, T., et al. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03764.x · Cited by 46
Pegram, H. J., Smith, E. L., Rafiq, S., & Brentjens, R. J. (2015) · Immunotherapy · doi:10.2217/imt.15.6 · Cited by 34
Reed, W., Noga, S. J., Gee, A. P., Rooney, C. M., Wagner, J. E., McCullough, J., McKenna, D. H., Whiteside, T. L., Donnenberg, A. D., Baker, A. K., et al. (2008) · Transfusion · doi:10.1111/j.1537-2995.2008.02027.x · Cited by 32
Cited by
Humanized Mouse Models of Clinical Disease
Walsh, N. C., Kenney, L. L., Jangalwe, S., Aryee, K.-E., Greiner, D. L., Brehm, M. A., & Shultz, L. D. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100332 · Cited by 562
Engineering Natural Killer Cells for Cancer Immunotherapy
Rezvani, K., Rouce, R., Liu, E., & Shpall, E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.012 · Cited by 453
Self-citationPrecision glycocalyx editing as a strategy for cancer immunotherapy
Xiao, H., Woods, E. C., Vukojicic, P., & Bertozzi, C. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608069113 · Cited by 440
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 419
CD56 in the Immune System: More Than a Marker for Cytotoxicity?
Van Acker, H. H., Capsomidis, A., Smits, E. L., & Van Tendeloo, V. F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00892 · Cited by 388
Metadata
- Authors
- Rezvani, K., & Rouce, R. H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2015-11-17
- Volume
- 6
- Pages
- 578-578
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2178588353
- Cited by
- 272
- References
- 106
- FWCI
- 12.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.